- Home
- AAME vs CGTX Comparison
AAME vs CGTX Comparison
Compare AAME & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAME
- CGTX
- Stock Information
- Founded
- AAME 1968
- CGTX 2007
- Country
- AAME United States
- CGTX United States
- Employees
- AAME N/A
- CGTX N/A
- Industry
- AAME Life Insurance
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AAME Finance
- CGTX Health Care
- Exchange
- AAME Nasdaq
- CGTX Nasdaq
- Market Cap
- AAME 35.1M
- CGTX 20.5M
- IPO Year
- AAME N/A
- CGTX 2021
- Fundamental
- Price
- AAME $1.69
- CGTX $0.24
- Analyst Decision
- AAME
- CGTX Strong Buy
- Analyst Count
- AAME 0
- CGTX 5
- Target Price
- AAME N/A
- CGTX $5.63
- AVG Volume (30 Days)
- AAME 11.0K
- CGTX 1.1M
- Earning Date
- AAME 05-13-2025
- CGTX 05-07-2025
- Dividend Yield
- AAME 1.18%
- CGTX N/A
- EPS Growth
- AAME N/A
- CGTX N/A
- EPS
- AAME N/A
- CGTX N/A
- Revenue
- AAME $191,355,000.00
- CGTX N/A
- Revenue This Year
- AAME N/A
- CGTX N/A
- Revenue Next Year
- AAME N/A
- CGTX N/A
- P/E Ratio
- AAME N/A
- CGTX N/A
- Revenue Growth
- AAME 2.04
- CGTX N/A
- 52 Week Low
- AAME $1.25
- CGTX $0.22
- 52 Week High
- AAME $1.99
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- AAME 54.05
- CGTX 28.50
- Support Level
- AAME $1.64
- CGTX $0.22
- Resistance Level
- AAME $1.92
- CGTX $0.34
- Average True Range (ATR)
- AAME 0.08
- CGTX 0.03
- MACD
- AAME -0.01
- CGTX -0.01
- Stochastic Oscillator
- AAME 28.13
- CGTX 14.41
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.